Navigation Links
BioRealm to Develop Universal Genetic Screening Tool for Tobacco Addiction and Treatment
Date:6/20/2012

Los Angeles, CA (PRWEB) June 20, 2012

BioRealm, LLC announced today that it has been awarded a Small Business Innovative Research contract by the U.S. National Institute on Drug Abuse (NIDA) to develop a universal genetic screening tool for tobacco addiction and treatment approaches. BioRealm’s “Smokescreen” product will integrate recent advances in tobacco addiction research and allow researchers to study thousands of an individual’s genetic variants related to tobacco dependence and treatment response.

According to the Centers for Disease Control and Prevention (CDC), smoking is the leading cause of preventable disease in the U.S., resulting in $96 billion in annual health care costs. Despite the availability of numerous smoking cessation products and treatments, effectiveness varies greatly and people often relapse. Studies have shown that genetic variation plays a significant role in nicotine dependence, including the ability to quit smoking and response to nicotine replacement therapy and medication. However, the genetics of tobacco addiction are not yet fully understood.

Addiction researchers have so far been limited by the small number of participants in clinical trials, and the lack of a validated genetic screening tool and centralized database for storing results. “The Smokescreen aims to solve these problems by featuring a uniform set of genetic variants, with genotyping results automatically stored and accessible via a secure cloud-based application”, stated Christopher Edlund, Bioinformatics Principal at BioRealm. “The ability to seamlessly share and compare data across multiple studies will enable researchers and clinicians to more effectively investigate tobacco addiction”.

Scientists at BioRealm envision the Smokescreen to be the standard genetic test used by clinical trials for smoking cessation. “The Smokescreen will be an invaluable resource for developing personalized smoking cessation treatments and ultimately reducing tobacco use in the U.S.”, said BioRealm co-founder Dr. James Baurley.

Additional information related to the Smokescreen product can be found at http://www.biorealmresearch.com/smokescreen.

About BioRealm

Founded in 2006, BioRealm develops solutions for genetic research and the biomedical industry.

Source: BioRealm, LLC

Read the full story at http://www.prweb.com/releases/2012/6/prweb9621970.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. NASA develops super-black material that absorbs light across multiple wavelength bands
2. Gated STED -- developing the next generation of super-resolution microscopes
3. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
4. Multidisciplinary team of researchers develop world’s lightest material
5. UCLA team develops highly efficient method for creating flexible, transparent electrodes
6. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
7. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
8. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
9. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
10. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
11. Researchers develop one of the worlds smallest electronic circuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017 Infectex Ltd., a Russian portfolio company of Maxwell Biotech ... SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... ( USA ) and the US National Institutes of Health. ... ... Fund Logo ...
(Date:3/27/2017)... , March 27, 2017  Perthera,s Chief Bioinformatics ... Center, Subha Madhavan , Ph.D., will be speaking ... Summits Panels. On Monday, March 27, 2017, she will ... Data More Usable for Research and Care" (from 10:30 ... 28, 2017, she will be a participant in the ...
(Date:3/27/2017)... ... 27, 2017 , ... PMG Research is pleased to announce its ... The Conference Forum in Boston on April 3-4, 2017. The CTC conference focuses on ... outcomes and bring them closer to the patient. Clinical Trial Collaborations also will present ...
(Date:3/27/2017)... SAN DIEGO , March 27, 2017  Trovagene, ... announced that its Chief Executive Officer, Bill Welch ... on April 4, 2017 at 9:00 AM EDT at ... .  Bill Welch, and Chief Scientific Officer, ... meet with investors during the conference.   The ...
Breaking Biology Technology:
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/1/2017)... BEDFORD, Mass. , March 1, 2017  Aware, ... and services, announced that Richard P. Moberg ... Officer and co-President and Chief Financial Officer and Treasurer ... will continue to serve as a member of the ... T. Russell , Aware,s co-Chief Executive Officer and co-President, ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
Breaking Biology News(10 mins):